Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001651308-24-000152
Filing Date
2024-11-12
Accepted
2024-11-12 06:06:42
Documents
98
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bgne-20240930.htm   iXBRL 10-Q 2244157
2 EX-31.1 exhibit311-2024q3.htm EX-31.1 9959
3 EX-31.2 exhibit312-2024q3.htm EX-31.2 9951
4 EX-32.1 exhibit321-2024q3.htm EX-32.1 6356
10 bgne-20240930_g1.jpg GRAPHIC 16225
  Complete submission text file 0001651308-24-000152.txt   10145217

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20240930.xsd EX-101.SCH 70928
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bgne-20240930_cal.xml EX-101.CAL 93295
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bgne-20240930_def.xml EX-101.DEF 303759
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20240930_lab.xml EX-101.LAB 729993
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20240930_pre.xml EX-101.PRE 538360
101 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20240930_htm.xml XML 1588824
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37686 | Film No.: 241442824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)